Analgesic efficacy of intravenous nefopam after spine surgery: a randomized, double-blind, placebo-controlled trial [version 2; peer review: 2 approved, 1 approved with reservations]

Jatuporn Eiamcharoenwit, Haruthai Chotisukarat, Kanjana Tainil, Nalinrat Attanath, Phuping Akavipat

Department of Anesthesiology, Prasat Neurological Institute, 312, Ratchawithi Road, Thung Phaya Thai, Ratchathewi, Bangkok, 10400, Thailand

First published: 04 Jun 2020, 9:516
https://doi.org/10.12688/f1000research.22909.1
Latest published: 26 Aug 2020, 9:516
https://doi.org/10.12688/f1000research.22909.2

Abstract

**Background:** The incidence of moderate to severe pain is high among patients undergoing spinal surgery. Nefopam can be used as an adjuvant analgesic postoperatively after spine surgery. The study aimed to assess the analgesic efficacy and side effects of nefopam on 24-hour postoperative morphine consumption after spine surgery.

**Methods:** The study is a randomized, double-blinded, placebo-controlled trial. A total of 96 patients were randomized into 4 treatment groups, 24 each. In group 1, patients received normal saline before surgical incision and before the end of surgery. In group 2, patients received 30 mg nefopam before surgical incision and normal saline before the end of surgery. In group 3, patients received normal saline before surgical incision and 30 mg of nefopam before the end of surgery. In group 4, patients received 30 mg of nefopam in both timings. Patient-controlled analgesia morphine was used for the postoperative period. Outcomes were to determine 24-hour morphine consumption and incidence of side effects.

**Results:** Of 96 patients enrolled, 21 in placebo-placebo, 22 in nefopam-placebo, 22 in placebo-nefopam and 21 in nefopam-nefopam groups completed the study. Analysis of the Kruskal-Wallis test shows no significant difference in 24-hour postoperative morphine consumption between four groups, which were 18 [IQR 13.5-29], 20 [IQR 11-28.3], 17 [IQR 11.5-28.5], 13 [IQR 8.5-18.5] mg., respectively (p = 0.223). Incidence of side effects, including tachycardia, sedation, sweating and nausea/vomiting, did not differ.

**Conclusions:** Adding perioperative nefopam to opioid analgesic does not improve analgesic efficacy in patients who underwent spine surgery.

**Registration:** Thai Clinical Trials Registry ID TCTR20171115001;
registered on 15 November 2017.

**Keywords**
Non-opioid analgesics; Postoperative pain; Morphine consumption
were administered during the perioperative period. Nefopam is a non-opioid analgesic drug used to treat postoperative pain. Mechanism of action is inhibiting the re-uptake of serotonin and norepinephrine. It also reduces glutamate release via modulating sodium and calcium channels. In previous studies, multiple timings of systemic nefopam were administered during the perioperative period. Nefopam was administered either before surgical incision, defined as preemptive analgesia, or at the end of surgery for post-operative pain control; however, the correct timing is not known. Therefore, the objectives of this study were to determine the analgesic efficacy and side effects of nefopam that administered before surgical incision, or before the end of the surgery, or both timings compared with placebo on postoperative morphine consumption.

Methods

Ethical issues

The study was a randomized, double-blinded, placebo-controlled trial. It was approved by the Institutional Review Board of Prasat Neurological Institute (IRBPNI) [Bangkok] and informed consent was obtained from all patients. The patients enrolled in the study comprised all patients undergoing spine surgery at Prasat Neurological Institute, February 2018 to March 2019.

Recruitment and allocation

Inclusion criteria were patient with age >18 years, who were undergoing lumbar sacral spine surgery under general anesthesia; elective case; not more than three-level spinal surgery; ASA physical status I-III; expected length of operation of 4–6 hours; and no history of nefopam or morphine allergy. Exclusion criteria were: patients with ischemic heart disease or arrhythmia; epilepsy; liver disease; creatinine clearance <30 ml/min; receiving neofopam within 24 hours or five elimination half-lives of neofopam; received strong opioids for more than 2 weeks or received monoxime oxidase inhibitor within 2 weeks before surgery; and who are unable to use a patient-controlled analgesia (PCA) device.

Patients were allocated into four treatment groups by the computer-generated random sequence and their allocation placed in a sealed envelope. A total of 96 patients were randomized into 4 treatment groups: 24 in placebo-placebo, 24 in neofopam-placebo, 24 in placebo-neofopam and 24 in neofopam-neofopam groups. The envelopes were opened only after the enrolled participants by the nurse anesthetists who was not involved in the study. All participants and researchers were blinded to the group allocation. At enrolment, patients were explained on a 0 to 10 numerical rating scale (NRS): 0 corresponds to no pain and 10 to the worst imaginable pain for postoperative pain assessment, and how to use the patient-controlled analgesia device on a day before surgery. Patients received premedication with 7.5 mg of midazolam within 30 - 60 minutes before anesthesia. No patients received NSAIDs, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressant, gabapentinoid or opioids on the morning of surgery.

Intervention

When the patients arrived at the operating theatre, each group of patients received two treatment timings: period A, 30 minutes before surgical incision; or period B, 30 minutes before the end of surgery or both timings compared with matching placebo. Nurse anesthetists not involved in the research project opened sealed envelopes containing the allocation to group
in the order of patients. Study medications were in identical appearance bottles; 100 ml of transparent, colorless solution, containing either 30 mg of nefopam (Acupan® BIOCODEX) or placebo, which was prepared in sealed envelopes by the nurse anesthetist who was not involved in the study. Study medications were given intravenously within 20 minutes each time. The treatment team and the data collector will not know which group of participants is in the study group. The patients were withdrawn and labels were opened if they exhibited a heart rate >150/min, arrhythmia, development of extreme unexpected events (such as acute ischemic heart disease, pulmonary embolism), and if the patient stopped using the PCA device before 24 hours after surgery.

In the operating theatre, Patients were monitored routinely with an electrocardiogram, noninvasive blood pressure, and pulse oximetry. Additionally, a bispectral index (BIS) monitor was utilized to assess the depth of anesthesia. Pre-oxygenation with high-flow oxygen through a facemask was given for 3 to 5 minutes. Anesthesia was then induced with intravenous propofol (1.5–2 mg/kg), and intravenous cisatracurium (0.15–0.2 mg/kg) was administered to facilitate the endotracheal intubation. Anesthesia was maintained at 1 MAC of desflurane with oxygen and nitrous oxide. Anesthesiologists provided cisatracurium and morphine by adjusting the depth of anesthesia to the Bispectral index (BIS) of 40–60. All patients received local wound infiltration with 20 ml of 0.5% bupivacaine at the end of the operation. At the recovery room, the patients were asked pain scores every 15 minutes using a numerical rating scale. If the pain score is greater than or equal to 4 points, the patients were injected with 2 mg of morphine every 10 minutes until the patients reported pain scores of less than 4. Then, the patients started to use the PCA device in the post-operative period. The PCA devices used in this study were IVAC® PCAM® Syringe Pumps (Alaris, United Kingdom). The protocol PCA setting of morphine 1 mg/ml; no basal rate, bolus dose of 1 mg, lockout interval of 5 minutes, 4-hour limit of 40 mg. If the patients required more than 40 mg of morphine within 4 hours, the cause of pain was reevaluated and neuropathic pain was ruled out by using the Thai-language Neuropathic Pain Diagnostic Questionnaire (Thai DN4)²⁶. Any other analgesics were not permitted during the study period.

Outcomes

Demographic data, American Society of Anesthesiologist (ASA) Physical status, comorbid disease, average pain score in a 24-hour period before surgery, operation, anesthetic time, duration of surgery, vital signs every 2.5 minutes during nefopam administration, intraoperative and 24 hours postoperative morphine consumption, first time to rescue morphine, pain score during postoperative 24 hours and side effects were recorded.

The primary outcome of the study was to determine the analgesic efficacy. The primary efficacy was defined as the cumulative morphine dose received 24 hours postoperatively by PCA during each time of nefopam administration. Secondary outcome comparisons were 24-hour postoperative pain score, and incidence of side effects such as tachycardia, sedation, sweating and nausea/vomiting. Sedation was defined as a Pasero Opioid-induced Sedation Scale (POSS) score that was greater than or equal to 3²³. Clinically important postoperative nausea and vomiting (PONV) were defined as PONV intensity scale of ≥75%.

Sample size calculation and statistical analysis

Previous studies have shown that when nefopam was given before the end of surgery, postoperatively 24-hour morphine consumption was 21.2 (15.3) mg. Morphine dose received 24 hours postoperatively in control group was 27.3 (19.2) mg²⁷. The sample size was determined from total postoperatively 24-hour morphine consumption. Neither the mean of 24-hour morphine consumption in the group receiving nefopam before surgical incision nor the group receiving nefopam before surgical incision plus at the end of surgery compared with placebo was reported in these previous studies. Therefore, this sample size estimated the level of reduction in 24-hour morphine consumption in both groups. The sample size gives the trial a power of 80%, sets a two-tailed α at 0.05 in means characterized by a variance of means of 11.792, assuming that the common standard deviation is 9.12. The calculation resulted in 21 patients per group. To compensate for 10% attrition rate, we included 24 patients per group. The total sample size is 96 patients. Criter-

Results

Patient eligibility and background

A total of 112 patients were eligible; 12 patients did not meet inclusion criteria and 4 patients declined to participate. As such, 96 patients were randomly assigned to the four groups: 21 in placebo-placebo, 22 in nefopam-placebo, 22 in placebo-nefopam and 21 in nefopam-nefopam groups. There were three patients in the placebo-placebo group, two patients in nefopam-placebo group, two patients in placebo-nefopam group, and three patients in nefopam-nefopam group were excluded from the analysis. Because 10 patients were unable to use patient-controlled analgesia device postoperatively. The total number of patients assessed was 86 (Figure 1).

Demographic characteristics of patients, preoperative pain score, number of surgical levels, surgery time and anesthetic time are shown in Table 1. The four groups are comparable in age, sex, body mass index, ASA Classification, type of operation, number of levels of spinal surgery, surgery time and anesthetic time. The demographic characteristics and baseline clinical characteristics of patients are similar.

The postoperative 24-hour morphine consumption (median [IQR]) for the placebo-placebo, nefopam-placebo, placebo-nefopam and
nefopam-nefopam groups were not different, at 18 [13.5–29], 20 [11–28.3], 17 [11.5–28.5], 13 [8.5–18.5] mg, respectively (p = 0.223). Time to first dose of morphine were not different, at 30 [7.5–85], 16.5 [10–41], 30 [12.5–67.5], 30 [12.5–91.5] min, respectively (p = 0.710). Pain score and total intraoperative morphine for four treatment groups were not different (Table 2). All raw data are available from Figshare.

The incidence of sedation, nausea and vomiting, sweating and intraoperative arrhythmia did not differ significantly between the groups (Table 3). No patients in four groups developed tachycardia. There was no statistically significant difference in heart rate between the four groups (Figure 2). No patients discontinued the treatment due to adverse events.

**Discussion**

The main results of this study showed no difference in 24 hours postoperatively morphine consumption between nefopam group and placebo. Additionally, the analgesic efficacy of nefopam that administered before surgical incision, or before the end of surgery, or both timings compared with placebo were similar. There were no significant differences in early or late side effects between the four groups. The result of this study was similar to previous studies. Merle et al. showed that nefopam given at the end of surgery and continuous infusion for 24–48 hours postoperatively, did not reduce morphine consumption. Similarly, Richebé et al. showed that nefopam given in three periods—at the induction of anesthesia, at the end of surgery and continuous infusion 48 hours postoperatively—did not significantly differ in 48 hours morphine consumption. Additionally, Cuvillon et al. showed that continuous intravenous 120 mg nefopam and placebo effects were not different at 48 hours after major abdominal surgery. These previous studies reported the efficacy of nefopam did not significantly differ to placebo, which might be because most of the previous studies studied the usual dose of nefopam 20 mg per dose by intravenous injection. Although intravenous administration of nefopam was given in a single dose of 20 mg, this gave an analgesic efficacy equivalent to 6–12 mg morphine. On the other hand, many previous studies reported that nefopam had analgesic efficacy to reduce the 24-hours postoperative morphine consumption by up to 19.2–51%. However, those studies studied patients who underwent minor or moderate surgery, such as laparoscopic or breast surgery, which caused mild to moderate post-operative pain (except for two studies that assessed hip arthroplasty and hepatic resection). The recommended dose of nefopam is 20 mg per dose by the manufacturer. The maximum dose of nefopam is no more than 120 mg per day. This study studied in patients who underwent spinal surgery that could cause moderate to severe pain. So, we used the dose of nefopam 30 mg per dose by intravenous injection which the dose
injected could be close to the median effective dose (ED50) of studies by Delage et al. and Beloeil et al. (28 and 27.3 mg), respectively. The side effects of the ED50 doses were not different from the control group. Another study reported that the ED50 of nefopam for postoperative analgesia in patients who have undergone laparoscopic cholecystectomy was 62.1 mg (95% CI, 52.9–72.9 mg). However, there were 27.6% and 20.7% of the patient developed pain upon injection and phlebitis, respectively. Nevertheless, the present study assessed a 30-mg dose of nefopam; the main result showed no difference in 24 hours postoperatively morphine consumption between nefopam group and placebo. This study reported negative outcomes, that may be a significant change in research result if 1) extension to the study duration of postoperative nefopam, 2) titration of nefopam dosage achieves an optimal dose and 3) the study design is conducted in patients undergoing minor to moderate surgery.

Our study had some limitations. Firstly, we studied a single dose of nefopam; no continuous intravenous infusion or around-the-clock dosing. However, the half-life of a single dose of nefopam administered intravenously is 3–5 hours, so the analgesic effect of one or two doses of nefopam did not extend to 24 hours postoperatively. Secondly, almost all patients only experienced preoperative mild to moderate pain. We suggested that perioperative nefopam administration has little analgesic effect, especially when given without opioids. The recommendation for clinical usage is used in combination or adjuvant therapy with the other types of analgesics or multimodal analgesia approach.

**Conclusion**

Adding perioperative nefopam to opioid analgesics does not improve analgesic efficacy in patients who underwent spine surgery.

---

**Table 1. Demographic characteristics of patients (n = 86).** Data given as n (%) or median [IQR].

| Variables                  | Placebo-Placebo (n = 21) | Nefopam-Placebo (n = 22) | Placebo-Nefopam (n = 22) | Nefopam-Nefopam (n = 21) | p-value |
|----------------------------|--------------------------|--------------------------|--------------------------|--------------------------|---------|
| Age, year                  | 67 [52.5-73.5]           | 57.5 [53.8-63.5]         | 55.5 [49.8-65.3]         | 59 [54.5-68.0]           | 0.082   |
| Female                     | 13 (61.9)                | 8 (36.4)                 | 14 (63.6)                | 12 (57.1)                | 0.242   |
| Body mass index, kg/m²     | 25.2 [22.5-32.1]         | 26.3 [23.5-27.3]         | 27.1 [22.6-29.4]         | 26.12 [22.4-28.4]        | 0.984   |
| ASA Classification         |                          |                          |                          |                          | 0.118   |
| I, II                      | 0, 12 (57.1)             | 4 (18.2), 16 (72.7)      | 2 (9.1), 15 (68.2)       | 2 (9.5), 12 (57.1)       |         |
| III                        | 9 (42.9)                 | 2 (9.1)                  | 5 (22.7)                 | 7 (33.3)                 |         |
| Type of Operation          |                          |                          |                          |                          | 0.93    |
| TLIF                       | 3 (14.3)                 | 0                        | 0                        | 2 (9.5)                  |         |
| TPS                        | 17 (81)                  | 22 (100)                 | 21 (95.5)                | 19 (90.5)                |         |
| Other                      | 1 (4.8)                  | 0                        | 1 (4.5)                  | 0                        | 0.447   |
| Number of levels           |                          |                          |                          |                          |         |
| 1, 2 surgical level        | 5 (23.8), 7 (33.3)       | 6 (27.3), 10 (45.5)      | 6 (27.3), 6 (27.3)       | 8 (38.1), 3 (14.3)       |         |
| 3 surgical levels          | 9 (42.9)                 | 6 (27.3)                 | 10 (45.5)                | 10 (47.6)                |         |
| Preoperative pain score    | 3.0 [2-5]                | 3.0 [1.3-4.8]            | 3.0 [0-6.0]              | 4.0 [2.3-5.0]            | 0.844   |
| Surgery time (min)         | 264 [233-294]            | 255 [208-295]            | 245 [220-280]            | 247 [226-321]            | 0.490   |
| Anesthetic time (min)      | 327 [288-372]            | 300 [255-352]            | 306 [289-350]            | 299 [271-348]            | 0.836   |
| Intraoperative morphine (mg)| 12 [10-15]               | 12.5 [10-15]             | 14 [11.5-15]             | 13 [10-14]               | 0.498   |

ASA Classification: American Society of Anesthesiologists Physical Status Classification System; TLIF: transforaminal lumbar interbody fusion; TPS: transpedicular screw.
Table 2. Postoperative pain score and postoperative morphine consumption.

| Variables                | Placebo-Placebo (n = 21) | Nefopam-Placebo (n = 22) | Placebo-Nefopam (n = 22) | Nefopam-Nefopam (n = 21) | p-value |
|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|---------|
| Pain score               |                          |                          |                          |                          |         |
| 0 hr                     | 1 [0-5]                  | 4 [0-5]                  | 1 [0-5]                  | 3 [0-5]                  | 0.989   |
| 4 hr                     | 5.5 [3-7.8]              | 5 [4-6.5]                | 5 [4-8]                  | 6 [5-7]                  | 0.856   |
| 8 hr                     | 5 [3-6]                  | 5 [4-6]                  | 4 [3-8.6]                | 5 [4-6.5]                | 0.686   |
| 12 hr                    | 5 [4.5-6]                | 5 [3-5.5]                | 5 [3-7]                  | 5 [3-6]                  | 0.732   |
| 16 hr                    | 5 [3.5-5.5]              | 4 [3-5]                  | 4.5 [3-6.5]              | 5 [3-6]                  | 0.469   |
| 20 hr                    | 4 [3-5]                  | 3.5 [3-5]                | 3.5 [3-5]                | 3 [3-5]                  | 0.963   |
| 24 hr                    | 4 [3-4.5]                | 3 [2-4.25]               | 3.5 [3-5]                | 4 [3-5]                  | 0.647   |
| Morphine bolus (mg)      |                          |                          |                          |                          |         |
| 0 - 4 hr                 | 3 [1-11]                 | 5 [4-11]                 | 5 [2-6.5]                | 3 [2-6.5]                | 0.623   |
| 0 - 8 hr                 | 7 [4-16]                 | 9 [6.75-12.3]            | 9 [3-9.5]                | 6 [4.5-10]               | 0.617   |
| 0 - 12 hr                | 11 [6-21.5]              | 12.5 [9-15.5]            | 10 [5-15]                | 9 [6-11.5]               | 0.361   |
| 0 - 16 hr                | 14 [8-26]                | 15.5 [11-19.5]           | 15 [6.5-21.5]            | 10 [7-14.5]              | 0.297   |
| 0 - 20 hr                | 16 [12-28]               | 19 [11-24.8]             | 17 [9-25]                | 12 [7.5-16]              | 0.259   |
| 0 - 24 hr                | 18 [13.5-29]             | 20 [11-28.3]             | 17 [11.5-28.5]           | 13 [8.5-18.5]            | 0.223   |
| Morphine consumption (mg)|                          |                          |                          |                          |         |
| 0 - 4 hr                 | 0                        | 0 [0-0.5]                | 0                        | 0 [0-2]                  | 0.236   |
| 0 - 8 hr                 |                          |                        |                          |                          |         |
| 0 - 12 hr                |                          |                        |                          |                          |         |
| 0 - 16 hr                |                          |                        |                          |                          |         |
| 0 - 20 hr                |                          |                        |                          |                          |         |
| 0 - 24 hr                |                          |                        |                          |                          |         |

Table 3. Side effects.

| Variables number of occurrences (%) | Placebo-Placebo (n = 21) | Nefopam-Placebo (n = 22) | Placebo-Nefopam (n = 22) | Nefopam-Nefopam (n = 21) | p-value |
|------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|---------|
| Sedation                           |                          |                          |                          |                          |         |
| 0 – 8 hr                           | 0                        | 3 (13.6)                 | 3 (13.6)                 | 3 (14.3)                 | 0.503   |
| 8 – 16 hr                          | 0                        | 1 (4.5)                  | 1 (4.5)                  | 0                        | 0.868   |
| 16 – 24 hr                         | 0                        | 0                        | 0                        | 0                        | -       |
| Nausea and vomiting                |                          |                          |                          |                          |         |
| 0 – 8 hr                           | 0                        | 1 (4.5)                  | 8 (36.4)                 | 9 (42.9)                 | 0.249   |
| 8 – 16 hr                          | 2 (9.5)                  | 1 (4.5)                  | 3 (13.6)                 | 0                        | 0.507   |
| 16 – 24 hr                         | 0                        | 1 (4.5)                  | 2 (9.1)                  | 1 (4.8)                  | 1.000   |
| Sweating                           |                          |                          |                          |                          |         |
| 0 – 8 hr                           | 0                        | 1 (4.5)                  | 2 (9.1)                  | 1 (4.8)                  | 1.000   |
| 8 – 16 hr                          | 1 (4.8)                  | 1 (4.5)                  | 2 (9.1)                  | 0                        | 0.801   |
| 16 – 24 hr                         | 2 (9.5)                  | 0                        | 2 (9.1)                  | 0                        | 0.142   |
| Arrhythmia – Period A              | 1 (4.8)                  | 2 (9.6)                  | 5 (23)                   | 0                        | 0.801   |
| Arrhythmia – Period B              | 0                        | 0                        | 0                        | 0                        | -       |
| At least one occurrence, n (%)     | 1 (4.8)                  | 2 (9.1)                  | 2 (9.1)                  | 3 (14.3)                 | 0.763   |

Period A: before surgical incision; Period B: before the end of surgery.
Figure 2. Heart rate in each group (median) before surgical incision (left) and at the end of surgery (right). Group 1: Placebo - Placebo; Group 2: Nefopam - Placebo; Group 3: Placebo - Nefopam; Group 4: Nefopam - Nefopam. There was no statistically significant difference in heart rate between groups.

Data availability

Underlying data

Figshare: Raw Data: Analgesic Efficacy of Intravenous Nefopam after Spine Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial. https://doi.org/10.6084/m9.figshare.12090753.v1.

This project contains the individual-level data for each participant.

Figshare: Information of abbreviation data set Title: Analgesic Efficacy of Intravenous Nefopam after Spine Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial Untitled Item. https://doi.org/10.6084/m9.figshare.12090753.v1.

This project contains definitions used in the above dataset.

Reporting guidelines

Figshare: CONSORT checklist for ‘Analgesic efficacy of intravenous nefopam after spine surgery: a randomized, double-blind, placebo-controlled trial’. https://doi.org/10.6084/m9.figshare.12033693.v4.

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

References

1. Bajwa SJ, Haldar R: Pain management following spinal surgeries: An appraisal of the available options. J Craniovertebr Junction Spine. 2015; 6(3): 105-10. PubMed Abstract | Publisher Full Text | Free Full Text
2. Sommer M, de Rijke JM, van Kleef M, et al.: The prevalence of postoperative pain in a sample of 1490 surgical inpatients. Eur J Anaesthesiol. 2008; 25(4): 267-74. PubMed Abstract | Publisher Full Text
3. Tobias JD: A review of intrathecal and epidural analgesia after spinal surgery in children. Anesth Analg. 2004; 98(4): 956-65. PubMed Abstract | Publisher Full Text
4. Fineberg SJ, Nandiyala SV, Kurd MF, et al.: Incidence and risk factors for postoperative ileus following anterior, posterior, and circumferential lumbar fusion. Spine J. 2014; 14(8): 1680-5. PubMed Abstract | Publisher Full Text
5. Buvanendran A, Thillainathan V: Preoperative and postoperative anesthetic and analgesic techniques for minimally invasive surgery of the spine. Spine (Phila Pa 1976). 2010; 35(26 Suppl):S274-80. PubMed Abstract | Publisher Full Text
6. Buvanendran A, Thillainathan V: Preventive Analgesic Efficacy of Nefopam for Postoperative Pain: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial. Eur J Anaesthesiol. 2015; 32(4): 269-74. PubMed Abstract | Publisher Full Text
7. Keleher M, Keleher H: Postoperative opioid sparing to hasten recovery: what are the unresolved issues? Anesthesiology. 2010; 112(1): 220-5. PubMed Abstract | Publisher Full Text
8. Puvanesarajah V, Liasuw JA, Lo SF, et al.: Analgesic therapy for major spine surgery. Neurosurg Rev. 2015; 38(3): 407-18; discussion 419. PubMed Abstract | Publisher Full Text
9. Devin CJ, McGirt MJ: Best evidence in multimodal pain management in spine surgery and means of assessing postoperative pain and functional outcomes. J Clin Neurusc. 2015; 22(6): 930-8. PubMed Abstract | Publisher Full Text
10. Lasans A, Benito P, Alonso J, et al.: Safe prescription recommendations for non steroidal anti-inflammatory drugs: consensus document elaborated by nominated experts of three scientific associations (SER-SEC-AEG). Reumatol Clin. 2014; 10(2): 68-84. PubMed Abstract | Publisher Full Text
11. Evans MS, Lysakowski C, Tramer MR: Nefopam for the prevention of postoperative pain: quantitative systematic review. Br J Anaesth. 2008; 101(5): 610-7. PubMed Abstract | Publisher Full Text
12. Verhey M, André N, Heulard I, et al.: Nefopam blocks voltage-sensitive sodium channels and modulates glutamatergic transmission in rodents. Brain Res. 2004; 1013(2): 249-55. PubMed Abstract | Publisher Full Text
13. Richebé P, Picard W, Rivat C, et al.: Effects of nefopam on early postoperative Hyperalgesia after cardiac surgery. J Cardiothorac Vasc Anesth. 2013; 27(3): 427-35. PubMed Abstract | Publisher Full Text
14. Yao JY, Lim BG, Kim H, et al.: The analgesic effect of nefopam combined with low dose remifentanil in patients undergoing middle ear surgery under desflurane anesthesia: a randomized controlled trial. Korean J Anesthesiol. 2015; 68(1): 43-49. PubMed Abstract | Publisher Full Text | Free Full Text
15. Na HS, Oh AY, Koo BW, et al.: Preventive Analgesic Efficacy of Nefopam in Acute and Chronic Pain After Breast Cancer Surgery: A Prospective,
Double-Blind, and Randomized Trial. Medicine (Baltimore). 2016; 95(20): e3705.
PubMed Abstract | Publisher Full Text | Free Full Text

Chaudakshetrin P, Prateepavanich P, Chira-Adisai W, et al.: Comparison of effects of intraoperative nefopam and ketamine infusion on managing postoperative pain after laparoscopic cholecystectomy administered remifentanil. Korean J Anesthesiol. 2016; 69(5): 480–6.
PubMed Abstract | Publisher Full Text | Free Full Text

Du Manoir B, Aubrun F, Langlois M, et al.: Randomized Prospective study of the Analgesic effect of nefopam after orthopaedic surgery. Br J Anaesth. 2003; 91(6): 836–41.
PubMed Abstract | Publisher Full Text

Mimoz O, Incagnoli P, Josse C, et al.: Nefopam: a randomized prospective comparison of effects of intraoperative nefopam and ketoprofen in postoperative patients: a study of interaction using sequential analysis and isobolographic analysis. Anesthesiology. 2005; 102(6): 1211–6.
PubMed Abstract | Publisher Full Text

Lee JH, Kim JH, Cheong YK: The analgesic effect of nefopam with fentanyl at the end of laparoscopic cholecystectomy. Korean J Pain. 2013; 26(4): 361–7.
PubMed Abstract | Publisher Full Text | Free Full Text

Park HJ, Park JU, Yoo W, et al.: Analgesic effects of nefopam in patients undergoing bimaxillary osteotomy: A double-blind, randomized, placebo-controlled study. J Craniomaxillofac Surg. 2016; 44(2): 210–4.
PubMed Abstract | Publisher Full Text

Cuvillon P, Zoric L, Demattei C, et al.: Opioid-sparing effect of nefopam in combination with paracetamol after major abdominal surgery: a randomized double-blind study. Minerva Anestesiol. 2017; 83(9): 914–20.
PubMed Abstract | Publisher Full Text

Chaudakshetrin P, Prateepavanich P, Chira-Adisai W, et al.: Cross-cultural adaptation to the Thai language of the neuropathic pain diagnostic questionnaire (DNA4). J Med Assoc Thai. 2007; 90(9): 1860–5.
PubMed Abstract

Pasero C: Assessment of sedation during opioid administration for pain management. J Perianesth Nurs. 2009; 24(3): 186–90.
PubMed Abstract | Publisher Full Text

Wengritzky R, Mettho T, Myles PS, et al.: Development and validation of a postoperative nausea and vomiting intensity scale. Br J Anaesth. 2010; 104(2): 158–66.
PubMed Abstract | Publisher Full Text

Eiamcharoenwit J: Raw Data: Analgesic Efficacy of Intravenous Nefopam after Spine Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial. figshare. Dataset. 2020.
http://www.doi.org/10.6084/m9.figshare.12029256

McLintock TT, Kenny GN, Howie JC, et al.: Assessment of the analgesic efficacy of nefopam hydrochloride after upper abdominal surgery: a study using patient controlled analgesia. Br J Surg. 1988; 75(8): 779–81.
PubMed Abstract | Publisher Full Text

Delage N, Maaliki H, Beloeil H, et al.: Median effective dose (ED50) of nefopam and ketoprofen in postoperative patients: a study of interaction using sequential analysis and isobolographic analysis. Anesthesiology. 2005; 102(6): 1211–6.
PubMed Abstract | Publisher Full Text

Beloeil H, Eurin M, Thévenin A, et al.: Effective dose of nefopam in 80% of patients (ED80): a study using the continual reassessment method. Br J Clin Pharmacol. 2007; 64(5): 686–93.
PubMed Abstract | Publisher Full Text | Free Full Text

Kim H, Lee DK, Lee MK, et al.: Median effective dose of nefopam to treat Postoperative Pain in patients who have undergone laparoscopic cholecystectomy. J Med Assoc Thai. 2007; 90(9): 1860–5.
PubMed Abstract | Publisher Full Text | Free Full Text

Eiamcharoenwit J: Information of abbreviation data set Title: Analgesic Efficacy of Intravenous Nefopam after Spine Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial. figshare. Dataset. 2020.
http://www.doi.org/10.6084/m9.figshare.12090753.v1

Eiamcharoenwit J: CONSORT checklist - Analgesic Efficacy of Intravenous Nefopam after Spine Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial. figshare. Dataset. 2020.
http://www.doi.org/10.6084/m9.figshare.12033693.v4
Soe Wunna Htay
Defence Services General Hospital, Yangon, Myanmar

This study is a randomized, double-blinded, placebo-controlled trial that used nefopam 30 mg perioperative period for assessing its efficacy in spine surgery. The study reported no morphine consumption reduction in the first 24 hours after spine surgery in the tested groups: placebo-placebo, preincisional nefopam-placebo, placebo-end surgery nefopam, preincisional and end surgery nefopam injections. The question I want to know is how much the amount of morphine used during the intraoperative period for adjusting the depth of anesthesia to the Bispectral Index (BIS) and should mention first during intervention.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: No competing interests were disclosed.
Reviewer Expertise: neuroanaesthesia

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 07 Sep 2020

Jatuporn Eiamcharoenwit, Prasat Neurological Institute, 312, Ratchawithi Road, Thung Phaya Thai, Ratchathewi, Thailand

Dear Dr. Soe Wunna Htay,

Thank you for your review and comment. Intraoperative morphine (mg) was showed in Table 1. We did not mention the amount of morphine used during the intraoperative period for adjusting the depth of anesthesia. Morphine dosage was at the discretion of anesthesiologists by adjusting the depth of anesthesia to the Bispectral Index (BIS) of 40–60.

Regards,
Jatuporn Eiamcharoenwit

Competing Interests: No competing interests were disclosed.

Reviewer Report 03 September 2020

https://doi.org/10.5256/f1000research.28724.r70304

© 2020 Seangrung R. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Rattaphol Seangrung
Department of Anesthesiology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

No further comments.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** pain management

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

---

**Francis Remérand**

1 Anaesthesiology and Critical Care Department, CHRU de Tours, Tours, France
2 University of Tours, Inserm U1253, Tours, France

This study reports no morphine consumption reduction in the 24 first hours after spine surgery in the 4 tested groups: placebo-placebo, single preincisional nefopam bolus – placebo, placebo-end surgery single nefopam bolus, preincisional and end surgery nefopam injections.

Despite a well design study (randomized monocentric double blind controlled study), major points have to be clarified, before interpreting the results.

**The sample size calculation is unclear:**

- In the methods chapter, it is calculated using a "percentage of reduction" of morphine consumption during the first 24 postoperative hours. The mean consumption to calculate the sample size is not given. By using the shared data of this study, the overall morphine consumption (N=96) is 22 mg +/- 20 (mean +/- standard deviation). With a power of 80%, an alpha at 0.05, 99 patients per group are required to detect the chosen 35% reduction in a two tailed test (https://biostatgv.sentiweb.fr), while the authors' calculation resulted in 21 patients per group. This study seems therefore largely underpowered.
The perioperative analgesic use should be more accurately described:
  ○ Was intraoperative analgesia obtained using morphine? (Methods, paragraph 6). If yes, the total dose should be mentioned in Table 2 (I suppose the 10-15mg intraoperative morphine mentioned in table 2 is for analgesia, not for a 6 hours anesthesia). Morphine was injected before the PACU in some patients (table 2 and data file): can you describe how the physician decided to inject or not morphine at the end of the surgery?
  ○ Methods, end of paragraph 4: no patient received preoperative gabapentinoid or opioid or NSAID. In the shared data file, 39/96 patients had gabapentinoid, 11 had NSAID and several had tramadol. Please explain these contradictory data.

Data analysis:
  ○ Results, first paragraph: 10 of 96 patients were excluded because operative time < 4 hours - Why did you choose such a limit? This is quite in opposition with the “intention to treat analysis” mentioned in the last paragraph of methods. Please explain why we find 39 patients (and not 10) with an operative time < 240 min in the shared data file. Please clearly identify in the shared file which patients have been excluded.
  ○ How were the lacking data seen in the shared data file managed? (“NA”).

Results:
  ○ Please replace in the third paragraph “similar” by “not different” (2 occurrences).
  ○ Table 3: are we dealing with nb of patients, nb of side effect occurrence? Can you mention cumulative data for patients (nb of patients having at least one occurrence of the side effect during the first 24 hours)?
  ○ I don't understand Figure 2: can you explain what each “time 0” is?
  ○ The detailed comments on the discussion have to be performed after the above points have been clarified. The global comment on discussion is that the main limitation of this study is it is largely underpowered. So conclusions about negative results have to be very cautious (more than in the present version of the paper). Nevertheless, these data have to be published, since they are fitted for a potential future meta-analysis.

Is the work clearly and accurately presented and does it cite the current literature?
  Yes

Is the study design appropriate and is the work technically sound?
  Partly

Are sufficient details of methods and analysis provided to allow replication by others?
  Partly

If applicable, is the statistical analysis and its interpretation appropriate?
  No
Are all the source data underlying the results available to ensure full reproducibility?
Partly

Are the conclusions drawn adequately supported by the results?
Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** anesthesiology and critical care

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 13 Aug 2020

**Jatuporn Eiamcharoenwit**, Prasat Neurological Institute, 312, Ratchawithi Road, Thung Phaya Thai, Ratchathewi, Thailand

Dear Dr. Francis Remérand,
Thank you for giving a chance to improve our research article. Hopefully, you would appreciate our revised version.

Regards,
Jatuporn Eiamcharoenwit

**Response to reviewer:**

This study reports no morphine consumption reduction in the 24 first hours after spine surgery in the 4 tested groups: placebo-placebo, single preincisional nefopam bolus – placebo, placebo-end surgery single nefopam bolus, preincisional and end surgery nefopam injections.

Despite a well designed study (randomized monocentric double-blind controlled study), major points have to be clarified, before interpreting the results.

**Comments:**

**The sample size calculation is unclear:**

In the methods chapter, it is calculated using a "percentage of reduction" of morphine consumption during the first 24 postoperative hours. The mean consumption to calculate the sample size is not given. By using the shared data of this study, the overall morphine consumption (N=96) is 22 mg +/- 20 (mean +/- standard deviation). With a power of 80%, an alpha at 0.05, 99 patients per group are required to detect the chosen 35% reduction in a two tailed test (https://biostatgv.sentireweb.fr), while the authors' calculation resulted in 21 patients per group. This study seems therefore largely underpowered.

**Response:** We changed the primary efficacy to "the primary efficacy was defined as the cumulative morphine dose received 24 hours postoperatively by Patient Controlled
Analgesia (PCA) during each time of nefopam administration” (Outcome, paragraph 2).

**Response:** According to previous study, PCA-administered morphine over 24 hours was significantly less for the nefopam group than control group 21.2 (15.3) and 27.3 (19.2) mg respectively; P=0.02). In nefopam group, patients received every 4-hour i.v. nefopam 20 mg. The first dose was infused in the operating room at the onset of deep-wound closure1.  

**Reference**  
1. Du Manoir B, Aubrun F, Langlois M, et al.: Randomized Prospective study of the Analgesic effect of nefopam after orthopaedic surgery. Br J Anaesth. 2003; 91:836-41.

We reanalyzed the sample size calculation. We will calculate sample size using One Way Analysis of Variance (ANOVA).

**Table 1:** The cumulative morphine dose received 24 hours postoperatively in 4 group.  
| Groups            | Cumulative morphine dose received 24 hours postoperatively, mg (SD) |
|-------------------|---------------------------------------------------------------------|
| Placebo - Placebo| 27.3 (19.2) using previous data1                                    |
| Nefopam - Placebo| 24 estimated from ascending                                          |
| Placebo - Nefopam | 21.2 (15.3) using previous data1                                     |
| Nefopam - Nefopam | 18 estimated from descending                                         |

Variance of means, V 11.792

**Table 2:** Power and Sample Size for One Way Analysis of Variance (ANOVA)  
| Test Significance Level, α | 0.05 |
| Number of Groups, G        | 4    |
| Variance of Means, V       | 11.792 |
| Common Standard Deviation, σ| 9.120 |
| Effect Size, Δ² = V/σ²     | 0.142 |
| Power (%)                  | 80   |
| Sample Size per Group, n   | 21   |

Previous studies have shown that when nefopam was given before the end of surgery, postoperatively 24-hour morphine consumption was 21.2 (15.3). When the sample size in each of the 4 groups is 21, a one-way analysis of variance will have 80% power to detect at the 5% level a difference in means characterized by a variance of means, V, of 11.792, assuming that the common standard deviation is 9.12.

**Response:** We revised information for the sample size calculation and statistical analysis chapter, paragraph 1. “Previous studies have shown that when nefopam was given before the end of surgery, postoperatively 24-hour morphine consumption was 21.2 (15.3) mg. Morphine dose received 24 hours postoperatively in control group was 27.3 (19.2) mg1. The sample size was determined from total postoperatively 24-hour morphine consumption. Neither the mean of 24-hour morphine consumption in the group receiving nefopam before surgical incision nor the group receiving nefopam before surgical incision plus at the end of surgery compared with placebo was reported in these previous studies. Therefore, this sample size estimated the level of reduction in 24-hour morphine consumption in both
groups. The sample size gives the trial a power of 80%, sets a two-tailed α at 0.05 in means characterized by a variance of means of 11.792, assuming that the common standard deviation is 9.12. The calculation resulted in 21 patients per group. To compensate for 10% attrition rate, we included 24 patients per group. The total sample size is 96 patients. 

(Sample size calculation and statistical analysis, paragraph 2).

The perioperative analgesic use should be more accurately described:
Was intraoperative analgesia obtained using morphine? (Methods, paragraph 6). If yes, the total dose should be mentioned in Table 2 (I suppose the 10-15mg intraoperative morphine mentioned in table 2 is for analgesia, not for 6 hours anesthesia). Morphine was injected before the PACU in some patients (table 2 and data file): can you describe how the physician decided to inject or not morphine at the end of the surgery? 

Response: (Methods, paragraph 6) Intraoperative morphine 10 – 15 mg was not for post operate analgesia. It was obtained for an average of 6 hours of anesthesia. So, we will move intraoperative morphine (mg) in table 2 to table 1.
Response: (table 2 and data file) The wording of MO_dose_beforePCA in the shared data file is a loading dose before the administration of Patient Controlled Analgesia (PCA) at PACU. It was not administered morphine before admitting the PACU.
At the PACU, the patients were asked pain scores every 15 minutes using a numerical rating scale. If the pain score is greater than or equal to 4 points, the patients were injected with 2 mg of morphine every 10 minutes until the patients reported pain scores of less than 4. Then, the patients started to use the PCA device in the post-operative period.

Methods, end of paragraph 4: no patient received preoperative gabapentinoid or opioid or NSAID. In the shared data file, 39/96 patients had gabapentinoid, 11 had NSAID and several had tramadol. Please explain these contradictory data.

Response: We wrote unclear. In the shared data file, the wording of Preop_Med is mean that current medications of patients. They were not premedication before day surgery. No patients received NSAIDs, gabapentinoid, or opioids on the morning of surgery. We change the word to “Current_Med” in the shared data file.

Data analysis:
Results, first paragraph: 10 of 96 patients were excluded because operative time < 4 hours - Why did you choose such a limit? This is quite in opposition with the “intention to treat analysis” mentioned in the last paragraph of methods. Please explain why we find 39 patients (and not 10) with an operative time < 240 min in the shared data file. Please clearly identify in the shared file which patients have been excluded.

Response: We have incorrectly written. Ten patients were unable to use patient-controlled analgesia (PCA) device postoperatively that cause patients to drop out of clinical trials. We change the sentence to “There were three patients in the placebo-placebo group, two patients in nefopam-placebo group, two patients in placebo-nefopam group and three patients in nefopam-nefopam group were excluded from analysis. Because 10 patients were unable to use patient-controlled analgesia device postoperatively” (Results, paragraph 1). The sample size was anticipated by 10% attrition rates.
Patients have been excluded who were number 31, 62 and 83 in placebo-placebo group, number 24 and 75 in nefopam-placebo group, number 69 and 73 in placebo-
nefopam group, number 41, 66 and 72 in nefopam-nefopam group. Ten patients in the shared data file are highlighted in yellow (Shared data file). We were correcting code for each group (Shared data file, Group).

Response: The sentence “The main analysis was analyzed by intention-to-treat (ITT)” was deleted. And, we change the sentence to “Safety data analysis was analyzed by a statistical chi-square test” (Sample size calculation and statistical analysis, paragraph 2).

Response: We change the sentence to “Analysis of the Kruskal-Wallis test shows no significant difference in 24-hour postoperative morphine consumption between four groups, which were 18 [IQR 13.5-29], 20 [IQR 11-28.3], 17 [IQR 11.5-28.5], 13 [IQR 8.5-18.5] mg., respectively (p = 0.223)” (The results section in an abstract)

How were the lacking data seen in the shared data file managed? (“NA”).

Response: The lacking data (“NA”) were 10 patients who were unable to use patient-controlled analgesia (PCA) device postoperatively. Ten patients who dropped out of the study (Shared data file, highlighted in yellow).

Results:

Please replace in the third paragraph “similar” by “not different” (2 occurrences).

Response: We replace the word to “not different” in the third paragraph of results.

Table 3: are we dealing with nb of patients, nb of side effect occurrence? Can you mention cumulative data for patients (nb of patients having at least one occurrence of the side effect during the first 24 hours)?

Response: The data were rechecked. We intended to report the occurrence of side effects. We change the word to “Variables, number of occurrences” in Table 3. We mentioned the number of patients having at least one occurrence of the side effect during the first 24 hours in the last row of table 3 (Table 3).

I don’t understand Figure 2: can you explain what each “time 0” is?

Response: Figure 2 – Heart rate at time 0 is heart rate before starting the study drug before surgical incision (Figure 2, left).

Heart rate at time 0 is heart rate at the end of surgery (Figure 2, right).

Competing Interests: No competing interests were disclosed.
This study is a randomized, double-blinded, placebo-controlled trial that used nefopam 30 mg perioperative period for assessing its efficacy in spine surgery. The primary efficacy was defined as the percentage of a reduction in 24-hour morphine consumption during each time of nefopam administration (every four hours). However, one question I have is why the results of morphine consumption (table 2) were showed in the only milligram of morphine consumption at each time point.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: pain management

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
Author Response 28 Jul 2020

Jatuporn Eiamcharoenwit, Prasat Neurological Institute, 312, Ratchawithi Road, Thung Phaya Thai, Ratchathewi, Thailand

Thank you for your review and comment. Because 24 hours postoperatively total opioid consumption in the placebo group is less than in nefopam groups, and the result shows no significant difference in 24-hour postoperative morphine consumption between four groups. So, the primary outcome was to determine the milligram of 24-hour morphine consumption.

**Competing Interests:** No competing interests were disclosed.

Author Response 13 Aug 2020

Jatuporn Eiamcharoenwit, Prasat Neurological Institute, 312, Ratchawithi Road, Thung Phaya Thai, Ratchathewi, Thailand

Dear Dr. Rattaphol Seangrung,

Thank you for giving a chance to improve our research article. We changed the primary efficacy to “the primary efficacy was defined as the cumulative morphine dose received 24 hours postoperatively by Patient Controlled Analgesia (PCA) during each time of nefopam administration”

We already edited as new version. Hopefully, you would appreciate our revised version.

Regards,
Jatuporn Eiamcharoenwit

**Competing Interests:** No competing interests were disclosed.
The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com